FARMACEUTSKI PATENTI: OPŠTE KARAKTERISTIKE I AKTUELNA PITANJA U MEĐUNARODNOPRAVNOM KONTEKSTU
Abstract
Farmaceutski patenti su posebna vrsta patenata, zbog načina i vremena potrebnog za njihovo patentiranje, kao i zbog njihovog uticaja na ljudska prava. Ovaj rad ima za cilj da čitaoce upozna sa opštim i jedinstvenim karakteristikama farmaceutskih patenata, kako bi se zatim upustio u diskusiju o aktuelnim ljudskopravnim aspektima u pogledu ovih patenata. Prvi deo rada uvodi čitaoca u materiju patentnog prava, dok se drugi bavi pitanjima odnosa farmaceutskih patenata i prava na zdravlje i pristup osnovnim lekovima.
Rad kombinuje tradicionalni pravni metod tumačenja sa sociološkim i ljudskopravnim pristupom. Takođe, treba naglasiti da se temi pristupa isključivo iz međunarodnopravog ugla, tako da će nacionalni i regionalni instrumenti i praksa biti uzimani u obzir samo kada mogu da posluže kao primer dobre prakse ili referenca. Na kraju, problematika će biti predstavljena iz perspektive nerazvijenih zemalja te problemi sa kojima se suočavaju određene grupe ljudi u razvijenim zemljama neće biti pokrivene.
References
Abbott, F. M., 2005, The WTO Medicines Decision: World Pharmaceutical Trade and Protection of Public Health, 99 AJIL.
Bentley, L., Sherman, B., 2009, Intellectual Property Law, 3rd Edition, Oxford University Press.
Bodenhausen, G. H. C., 1968, Guide to the Application of the Paris Convention for the Protection of Industrial Property as Revised in Stockholm in 1967, BIRPI.
Commission of Intellectual Property Rights, 2002, Integrating Intellectual Property Rights and Development Policy (http://www.iprcommission.org/papers/pdfs/final_report/CIPRfullfinal.pdf).
Commission on Intellectual Property Rights, Innovation and Public Health, 2006, Public Health, Innovation and Intellectual Property Rights, WHO, (http://www.who.int/intellectualproperty/documents/thereport/ENPublicHealthReport.pdf).
Correa, C. M., 2004, Ownership of knowledge- the role of patents in pharmaceutical R&D, Bulletin of the WHO, 82.
Correa, C. M., 2006, ICTSD, WHO, UNCTAD Guidelines for the examination of pharmaceutical patents: developing a public health perspective – A Working Paper (http://ictsd.net/downloads/2008/06/correa_patentability20guidelines.pdf).
Correa, C. M. (ed.), 2008, A Guide to Pharmaceutical Patents, Vol. I (http://www.southcentre.org/index.php?option=com_content&task=view&id=678&Itemid=1).
Damnjanović, K., Marić, V., 2007, Intelektualna svojina, Drugo izmenjeno izdanje, Beograd, Pravni fakultet Univerziteta Union, Službeni glasnik.
European Patent Office, 2010, Guidelines for Examination in the European Patent Office (http://documents.epo.org/projects/babylon/eponet.nsf/0/7ffc755ad943703dc12576f00054cacc/$FILE/guidelines_2010_complete_en.pdf).
Flynn, S., 2003, Legal Strategies for Expanding Access to Medicines, 17 Emory Int’l L. Rev.
Helfer, L. R., Austin, G. W., 2011, Human rights and intellectual property: mapping the global interface, Cambridge University Press.
Hestermeyer, H., 2008, Human Rights and the WTO: The Case of Patents and Access to Medicines, Oxford University Press.
Hogerzeil, H. V., Mirza, Z., 2011, The World Medicines Situation 2011: Access to Essential Medicines as Part of the Right to Health, 3rd Edition, WHO.
Hoen, E. F. M. ’t, 2003, TRIPS, Pharmaceutical Patents and Access to Essential Medicines: Seattle, Doha and Beyond, (http://www.who.int/intellectualproperty/topics/ip/tHoen.pdf).
Hunt, P., Khosla, R., The Human Right to Medicines, 2008, SUR– IJHR, Year 5, No. 8.
Killick, J., Schultz A., Dawes A., 2008, The Stockholm Network Experts’ Series on Pharmaceutical Intellectual Property Rights: The special regime of intellectual property for the pharmaceutical industry, Stockholm Network.
Komitet za ekonomska, socijalna i kulturološka prava, 2000, Generalni komentar broj 14. Pravo na najviši mogući standard zdravlja (član 12. Međunarodnog pakta o ekonomskim, socijalnim i kulturološkim pravima), E/C.12/2000/4 (http://www.refworld.org/docid/4538838d0.html).
Milenijumski ciljevi razvoja UN, cilj 8: Pružanje globalnog partnerstva za postizanje milenijumskih razvojnih ciljeva, Izveštaj radne grupe za Milenijumske ciljeve razvoja, 2008,(http://www.un.org/millenniumgoals/pdf/MDG%20Gap%20Task%20Force%20Report%202008.pdf).
Pogge, T., Rimmer, M., Rubenstein, K. (eds.), 2010, Incentives for Global Health: Patent Law and Access to Essential Medicines, Cambridge University Press.
Sun, H., 2004, The Road to Doha and Beyond; Some reflections on the TRIPS Agreement and Public Health, European Journal of International Law, Vol. 15 No. 1.
Specijalni izvestilac UN za pravo svakog na uživanje najvišeg mogućeg standarda fizičkog i mentalnog zdravlja, Pol Hant (Paul Hunt), 2008, Human Rights Guidelines for Pharmaceutical Companies in relation to Access to Medicines, A/63/263.
Specijalni izvestilac UN za pravo svakog na uživanje najvišeg mogućeg standarda fizičkog i mentalnog zdravlja, Pol Hant (Paul Hunt), The right of everyone to the enjoyment of the highest attainable standard of physical and mental health, E/CN.4/2004/49/Add.1.
Tritton, G. et al., 2002, Intellectual Property in Europe, 2nd Edition, Sweet and Maxwell.
UN Millennium Project, 2005, ‘Prescription for Healthy Development: Increasing Access to Medicines’, Report of the Task Force on HIV/AIDS, Malaria, TB, and Access to Essential Medicines, Working Group on Access to Essential Medicines, Earthscan (http://www.unmillenniumproject.org/documents/TF5-medicines-Complete.pdf).
UN Savet za ljudska prava, Izveštaj Specijalnog izvestioca UN za pravo svakog na uživanje najvišeg mogućeg standarda fizičkog i mentalnog zdravlja, Ananda Grovera (Anand Grover), A/HRC/11/12.